Clinical Trials Sponsored by Opal Rheumatology Ltd.

Total 31 results

Opal Rheumatology Ltd.
Merck Sharp & Dohme LLC

Unknown

Investigating the Utilisation and Effectiveness of Originator and Biosimilar Anti-TNF Agents

Rheumatoid Arthritis | Psoriatic Arthritis | Ankylosing Spondylitis

Australia
Ottawa Heart Institute Research Corporation
PAL Technologies Ltd.

Completed

Sedentary Intervention Trial in Cardiac Rehabilitation (SIT-CR)

Coronary Artery Disease

Canada
Grupo de Investigação em Bioquímica e Biologia...
University of Lisbon; Dentaid SL; Portuguese Institute of Rheumatology

Completed

Quality of Life and Sjögren Syndrome

Quality of Life | Sjogren's Syndrome | Xerostomia | Hyposalivation
Horizon Pharma Ireland, Ltd., Dublin Ireland
Pediatric Rheumatology Collaborative Study Group

Completed

Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis

Juvenile Idiopathic Arthritis

United States
Institute of Hematology & Blood Diseases Hospital...
Sinocelltech Ltd.

Recruiting

ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor

Hemophilia A With Inhibitor

China
Institute of Hematology & Blood Diseases Hospital
Cellular Biomedicine Group Ltd.

Recruiting

ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM)

Multiple Myeloma

China
Institute of Hematology & Blood Diseases Hospital
Xian-Janssen Pharmaceutical Ltd.

Not yet recruiting

R-EPOCH in Combination With Ibrutinib for Patients With Classical RT of CLL (BDHRT001)

Richter Transformation

China
Institute of Hematology & Blood Diseases Hospital
Juventas Cell Therapy Ltd.

Completed

CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma

Relapse | Lymphomas Non-Hodgkin's B-Cell

China
Institute of Hematology & Blood Diseases Hospital
Cellular Biomedicine Group Ltd.

Completed

A Study of C-CAR066 in Subjects With r/r Diffuse Large B Cell Lymphoma Who Received CD19 CAR-T Therapy

Diffuse Large B Cell Lymphoma

China
Institute of Hematology & Blood Diseases Hospital
Juventas Cell Therapy Ltd.

Available

A Clinical Study of CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies

Relapsed and Refractory Hematological Malignancies

China
Institute of Hematology & Blood Diseases Hospital
Juventas Cell Therapy Ltd.

Active, not recruiting

CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)

Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia

China
Institute of Hematology & Blood Diseases Hospital
Hangzhou Qihan Biotech Co.,Ltd.

Not yet recruiting

Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia

Minimal Residual Disease | AML, Adult

China
Institute of Hematology & Blood Diseases Hospital
MethylGene Tech Co., Ltd. China

Recruiting

ctDNA Methylation Sequencing for Myeloma

Multiple Myeloma

China
Institute of Hematology & Blood Diseases Hospital...
Juventas Cell Therapy Ltd.

Recruiting

CNCT19 for Patients With Autoimmune Hemolytic Anemia After Failure ≥3 Lines of Therapy.

Autoimmune Hemolytic Anemia | Autologous CD19 CAR-T | Failure of Three or More Lines of Therapy

China
Institute of Hematology & Blood Diseases Hospital
Hangzhou Qihan Biotech Co.,Ltd.

Recruiting

Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia

AML, Adult

China
Institute of Hematology & Blood Diseases Hospital
Shanghai Kuaixu Biotechnology Co., Ltd

Recruiting

Using Mass Spectrometry (EasyM) Detecting Minimal Residual Disease (MRD) in Multiple Myeloma

Multiple Myeloma

China
Institute of Hematology & Blood Diseases Hospital...
Shanghai Vitalgen BioPharma Co., Ltd.

Recruiting

Safety and Efficacy Evaluation of Autologous CRISPR-Cas12b Edited Hematopoietic Stem Cells

Thalassemia Major | Thalassemia, Beta

China
Institute of Hematology & Blood Diseases Hospital...
Jiangsu Hengrui Pharmaceuticals Co.,Ltd

Recruiting

Herombopag Added to Cyclosporine in Non Severe Aplastic Anemia

Non Severe Aplastic Anemia | Untreated

China
Institute of Hematology & Blood Diseases Hospital...
CSPC Ouyi Pharmaceutical Co., Ltd.

Active, not recruiting

GVM±R in Patients With Relapsed or Refractory Aggressive NHL

Non Hodgkin Lymphoma

China
Institute of Hematology & Blood Diseases Hospital
China Immunotech (Beijing) Biotechnology Co., Ltd.

Not yet recruiting

YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

China
Qiu Lugui
Jiangsu Hengrui Pharmaceuticals Co.,Ltd

Recruiting

Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma

Lymphoma | Multiple Myeloma

China
Zou Dehui
Juventas Cell Therapy Ltd.

Active, not recruiting

CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma

Large B-cell Lymphoma

China
Qiu Lugui
Guangzhou Burning Rock Dx Co., Ltd.

Recruiting

Assessment of Early Detection and Prognosis Based on cfDNA Methylation in Multiple Myeloma

Multiple Myeloma

China
Institute of Hematology & Blood Diseases Hospital
Juventas Cell Therapy Ltd.; Union Stem cell & gene engineering Co.LTD

Completed

CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia, Adult B-Cell | Acute Lymphoblastic Leukaemia Recurrent

China
Institute of Hematology & Blood Diseases Hospital
Shanghai Cell Therapy Engineering Technology Research Center Group Co., Ltd.

Unknown

Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma

Diffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma | Primary Mediastinal Large B Cell Lymphoma | Transformed Lymphoma

China
Shanghai Cell Therapy Group Co.,Ltd
Institute of Hematology & Blood Diseases Hospital; Tianjin Medical University...

Unknown

Study of Safety and Efficacy of BZ019 in (R/R) Large B-cell Lymphoma

Large B-cell Lymphoma

China
Institute of Hematology & Blood Diseases Hospital
Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Beijing...

Recruiting

Allogeneic γδ T Cells Immunotherapy in r/r Non-Hodgkin's Lymphoma (NHL) or Peripheral T Cell Lymphomas (PTCL) Patients

Non-Hodgkin's Lymphoma (NHL) | Peripheral T Cell Lymphoma (PTCL)

China
Institute of Hematology & Blood Diseases Hospital
Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Beijing...

Unknown

γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)

Non-Hodgkin's Lymphoma | Peripheral T Cell Lymphoma | Relapsed or Refractory B Cell Non-Hodgkin's Lymphoma | Chronic Lymphoblastic Leukemia

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Peking University People's Hospital; The First Affiliated Hospital of Zhengzhou... and other collaborators

Recruiting

PA3-17 Injection Treatment of Adult Patients With CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies

CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies

China
Institute of Hematology & Blood Diseases Hospital...
Xijing Hospital; Xi'an Central Hospital; The Second Hospital of Hebei Medical... and other collaborators

Active, not recruiting

A Randomized Trial Comparing Optimized rhTPO Treatment With Eltrombopag Treatment in Pre-treated ITP Pts (TE-ITP)

Previously Treated Primary Immune Thrombocytopenia

China
Shandong Qilu Stem Cells Engineering Co., Ltd.
Second Affiliated Hospital of Zhengzhou University; The Second Affiliated Hospital... and other collaborators

Recruiting

Clinical Study of UCB Combined With UC-MSCs in the Treatment of Bone Marrow Failure Disorders

Bone Marrow Failure Disorders

China

Clinical Trials Sponsored by Opal Rheumatology Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hungary

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations